Not recruiting
Triple negative breast cancer+1
Not recruitingStudy of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations
Registered drugNo placebo
Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations
Registered drugNo placebo
- Disease:Triple negative breast cancerHormone receptor positive HER2 negative breast cancer
- Substances:EribulinIzorlisib Mesilate
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Eribulin
